Neurology

FDA OKs Immunoglobulin Xembify for Primary Immunodeficiencies

Xembify is a 20% immune globulin solution for subcutaneous injection indicated to treat primary immunodeficiencies in patients aged 2 years and older.
FDA Approvals

Source link




Related posts

Neutrophil extracellular traps in the central nervous system hinder bacterial clearance during pneumococcal meningitis

Newsemia

First Generic Version of Sabril Tablets Gets FDA Approval

Newsemia

How emotions may impact tumor growth

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy